The 20 Best Primitive Neuroectodermal Tumor (PNET) Doctors Near Me in Maryland, US

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Henry Brem is a Neurosurgery provider in Baltimore, Maryland. Dr. Brem is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Gliosarcoma, Glioma, Gliomatosis Cerebri, Osteotomy, and Posterior Fossa Decompression.

Christopher Jackson is a neurosurgeon who specializes in brain tumors and cerebrovascular disorders, including glioma, meningioma, acoustic neuroma, trigeminal neuralgia, brain metastasis, arteriovenous malformation, and aneurysms. He is the director of the Acoustic Neuroma Center. Dr. Jackson earned his medical degree from the Johns Hopkins University School of Medicine, where he also completed his neurosurgical residency. During his residency, Dr. Jackson was honored with multiple distinctions, including the Frank L. Coulson Jr. Award for Clinical Excellence, the Irving J. Sherman Award for Resident Achievement, the Harvey Cushing Hunterian Research Award, and was elected to Alpha Omega Alpha. Dr. Jackson is an active researcher who has published over 35 peer-reviewed articles on brain tumor and cerebrovascular immunology. His laboratory focuses on how brain tumors evade the immune system and become resistant to immunotherapy. Additionally, Dr. Jackson’s laboratory explores the formation of cerebral aneurysms and inflammatory complications of cerebral aneurysm rupture. Dr. Jackson is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Dysembryoplastic Neuroepithelial Tumors (DNET), Brain Stem Cancer, Posterior Fossa Tumor, Awake Craniotomy, and Gastrostomy.

David Kamson is an Oncologist in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Brain Tumor, Glioblastoma, Metastatic Brain Tumor, Gliosarcoma, and Hormone Replacement Therapy (HRT).

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Richard Strauss, MD, specializes in neurosurgery. He practices at UPMC Western Maryland Neurosurgery. Dr. Strauss completed his residency at Icahn School of Medicine at Mount Sinai Medical and medical education at University of Maryland School of Medicine. Dr. Strauss is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Delirium, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Bone Graft, and Vertebroplasty.

Richard Choi is a Neurologist in Glen Burnie, Maryland. Dr. Choi has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Stroke, Apoplexy, Subarachnoid Hemorrhage, Stent Placement, and Transmyocardial Revascularization.

Vijay Maggio is a Neurologist in Columbia, Maryland. Dr. Maggio has been practicing medicine for over 34 years and is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Cervical Myelopathy, Spinal Tumor, Subependymoma, and Brain Stem Cancer. Dr. Maggio is currently accepting new patients.

Dr. Peter Kaplan is Professor of Neurology and serves as the Director of Epilepsy and EEG at Johns Hopkins Bayview Medical Center. He focuses on epilepsy, clinical neurophysiology and nonconvulsive status epilepticus. He has written extensively about these subjects as well as about eclampsia and neurologic disease in women. Dr. Peter Kaplan received his medical training from St. Bartholomews Medical School, University of London. He then obtained membership to the Royal College of Physicians in England. He completed his residency in neurology at Duke University Medical Center. He completed fellowships in epilepsy and clinical neurophysiology at the same institution. Dr. Kaplan currently sees patients at the Johns Hopkins Bayview Medical Center on Tuesdays and Wednesdays. Dr. Kaplan is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Seizures, Generalized Tonic-Clonic Seizure, Status Epilepticus, Epilepsy, and Awake Craniotomy.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Carl Ansevin is a Neurologist in Columbia, Maryland. Dr. Ansevin is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Cervical Myelopathy, Dysembryoplastic Neuroepithelial Tumors (DNET), Brain Stem Cancer, and Posterior Fossa Tumor.

Frederick Nahm is a Neurologist in Columbia, Maryland. Dr. Nahm is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Cervical Myelopathy, Dysembryoplastic Neuroepithelial Tumors (DNET), Brain Stem Cancer, and Invertebral Disc Disease.

Sherley Valdez is a Neurologist in Columbia, Maryland. Dr. Valdez has been practicing medicine for over 21 years and is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Cervical Myelopathy, Dysembryoplastic Neuroepithelial Tumors (DNET), Brain Stem Cancer, and Hemangioblastoma. Dr. Valdez is currently accepting new patients.